Prenatal hypocalvaria after prolonged intrauterine exposure to angiotensin II receptor antagonists | Zendy

Marine Lallemant | Zendy; Sarah Prévost | Zendy; François Nobili | Zendy; D. Riethmuller | Zendy; R. Ramanah | Zendy; MarieFrance Seronde | Zendy; Nicolas Mottet | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prenatal hypocalvaria after prolonged intrauterine exposure to angiotensin II receptor antagonists

Author(s) -

Marine Lallemant,

Sarah Prévost,

François Nobili,

D. Riethmuller,

R. Ramanah,

MarieFrance Seronde,

Nicolas Mottet

Publication year - 2018

Publication title -

journal of the renin-angiotensin-aldosterone system

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.457

H-Index - 46

eISSN - 1752-8976

pISSN - 1470-3203

DOI - 10.1177/1470320318810940

Subject(s) - medicine , fetus , pregnancy , endocrinology , renin–angiotensin system , biology , blood pressure , genetics

We report a case of prenatal exposure to angiotensin II receptor antagonists (ARA II) from the beginning of pregnancy in a patient with a hypokinetic dilated cardiomyopathy. This case report emphasizes the fetal renal impact of prolonged intrauterine exposure to renin-angiotensin system (RAS) blockers, and highlights that this exposure can cause severe prenatal hypocalvaria. This delayed ossification can be reversible after birth, but the presence of anhydramnios indicates an early and irreversible block of RAS blockers in the fetus that is responsible for fetal kidney development abnormalities. This association carries a high risk of neonatal death. Prolonged exposure to ARA II or other RAS blockers remains prohibited throughout pregnancy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research